Skip to main content
ASTAL LABORATORIES LIMITED logo

ASTAL LABORATORIES LIMITED — Investor Relations & Filings

Ticker · 512600 ISIN · INE307N01014 LEI · 8945004HO2WCBQ0CJ976 BSE.NS Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country IN India
Listing BSE.NS 512600

About ASTAL LABORATORIES LIMITED

https://miel.co.in/

Astal Laboratories Limited is a pharmaceutical organization engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company's product portfolio encompasses various dosage forms, including tablets, capsules, liquid orals, and topical preparations. It operates across several therapeutic categories, such as anti-infectives, analgesics, and gastrointestinal treatments. Astal Laboratories prioritizes quality control and adheres to established manufacturing standards to ensure the safety and efficacy of its products. The company focuses on providing accessible healthcare solutions through a robust distribution network and a commitment to research-driven formulation development.

Recent filings

Filing Released Lang Actions
Intimation of authorization of KMPs under regulation 30 (5) of SEBI (LODR), Regulations, 2015.
Regulatory Filings Classification · 90% confidence The document is a disclosure letter filed under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, informing the exchange of the appointment of Key Managerial Personnel authorized for materiality determinations and exchange disclosures. It is a compliance announcement to the stock exchange and does not contain substantive financial statements, earnings data, or presentation material. It falls under general regulatory announcements or filings, making “Regulatory Filings (RNS)” the appropriate category.
2026-06-01 English
Internal Auditor appointment for the financial year 2026-27.
Regulatory Filings Classification · 80% confidence The document is a corporate announcement under Regulation 30 of SEBI LODR informing the stock exchange of the re‐appointment of the company’s internal auditor. It is a short compliance notice to the exchange rather than a standalone financial report or detailed governance policy. This falls under general regulatory filings (fallback) rather than management change, report publication, or financial reporting categories.
2026-05-31 English
Financial Results for quarter and year ended March 31, 2026
Audit Report / Information Classification · 92% confidence The document is a formal exchange filing dated May 30, 2026, from Astal Laboratories Limited to the BSE, submitting “Revised Audited Standalone and Consolidated Financial Results” for the quarter and year ended March 31, 2026 under SEBI LODR Regulation 33. It contains the company’s cover letter, approval details, and the full independent auditor’s reports (for standalone and consolidated results) with opinion, basis, management and auditor responsibilities. It does not constitute the full Annual Report or mere highlights, but is specifically the audit opinion and related audit information on the company’s financial results. This aligns precisely with the “Audit Report / Information” category (Code: AR), which covers standalone audit reports and related disclosures (excluding a full Annual Report). FY 2026
2026-05-30 English
Statement of Deviation and variation
Regulatory Filings Classification · 87% confidence The document is a “Statement of Deviation and Variation in Utilisation of Funds Raised” filed under Regulation 32 of the SEBI (LODR) Regulations to BSE. It is a mandatory quarterly compliance disclosure rather than an actual fundraising announcement or financial report. It does not present new financial statements or raise capital; rather, it is a regulatory compliance filing under listing obligations. Therefore, it falls under general Regulatory Filings (RNS).
2026-05-30 English
Audited standalone and consolidated financial results for the quarter and financial year ended March. 31, 2026.
Interim / Quarterly Report Classification · 92% confidence The document is the company’s audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, containing full financial statements (income statement, balance sheet, cash flow statement) and notes. It is issued under SEBI LODR Regulation 33, not an annual report or mere announcement, and includes substantive financial data beyond headline highlights. This matches the definition of an Interim/Quarterly Report (comprehensive financial report for a period shorter than a full fiscal year). FY 2026
2026-05-30 English
Outcome of Board Meeting held on Saturday, 30th May, 2026.
Interim / Quarterly Report Classification · 80% confidence The document is a SEBI LODR Regulation 30/33 filing of audited standalone and consolidated quarterly (and year-to-date) financial results approved by the board, together with the auditor’s reports. It is long (>>5,000 chars) and contains the actual audit opinions and references to the audited financial statements, not just a notice that a report is published. This aligns with a full Interim/Quarterly Report rather than an earnings teaser or a pure audit opinion. Therefore, it should be classified as an Interim/Quarterly Report (IR). FY 2026
2026-05-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.